Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,230 recruiting studies in this area right now.
By phase
- Not applicable3,143
- Phase 21,065
- Phase 1821
- Phase 1/Phase 2445
- Phase 3424
- Phase 4238
- Phase 2/Phase 394
Top conditions
- Multiple Sclerosis341
- Multiple Myeloma332
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis141
- Type 1 Diabetes133
- Atopic Dermatitis128
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia122
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)66
- Leukemia64
- Acute Myeloid Leukemia62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals63
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California494
- Maryland196
- Alabama175
- Florida143
- Arizona140
- New York123
- Massachusetts119
- Texas118
- Illinois81
- Colorado77
Recruiting studies6,230 total
- NCT05595447RecruitingPhase 2/Phase 3
Testing new treatment for Hodgkin lymphoma that came back
This study tests a treatment plan for adults with Hodgkin lymphoma that has returned or did not respond to ABVD chemotherapy. It may help people with a higher-risk pattern of disease, as long as their organ function and overall health meet study limits.
León, GuanajuatoAges 15–90 - NCT05595577Recruiting
Personalized exercise program to improve fitness during cancer care
This trial tests whether a tailored, home-based exercise plan can improve exercise capacity (how far and how safely you can be active) in people receiving cancer treatments that may affect the heart. It may help you build safer stamina while monitoring your heart health.
Winston-Salem, North CarolinaAges 18–85 - NCT05597345RecruitingPhase 2
Selinexor for higher-risk smoldering myeloma
This trial studies selinexor, a medicine taken by mouth, to slow or treat intermediate- or high-risk smoldering multiple myeloma before it becomes symptomatic. It may help some people reduce disease progression, based on how well the treatment controls the abnormal plasma cells.
Rochester, New YorkAges 18 years+ - NCT05597904Recruiting
Study differences in celiac disease and related skin rash
This study looks at why celiac disease (and a related skin condition called dermatitis herpetiformis) can look different from person to person. It may help researchers understand these “phenotypes” (different patterns) so future care can be better targeted.
TampereAges 18 years+ - NCT05599880RecruitingPhase 2
Bortezomib for adults with hard-to-treat immune low platelets
This Phase 2 trial tests whether bortezomib can safely increase platelet counts in adults with immune thrombocytopenia (ITP) that keeps coming back or doesn’t respond to standard treatments. It’s for people with very low platelets who still need treatment despite prior medicines.
Guri-siAges 19 years+ - NCT05600920RecruitingPhase 1/Phase 2
Long-acting IL-7 drug trial for low CD4 immune cells
This Phase 1/2 study tests a long-acting IL-7 medicine to raise low CD4 immune cells in people with idiopathic CD4 lymphopenia. Because this is a dose-escalation study, the goal is to check safety and see if the treatment affects immune cell levels.
Bethesda, MarylandAges 18–75 - NCT05602376Recruiting
HIV messages to help men get tested and stay in care
This study tests whether special “U=U” style messages can improve how men move from HIV testing to starting treatment and continuing care. You may be asked to receive guidance and information meant to help you stay engaged in HIV treatment.
East London, Eastern CapeAges 15 years+ - NCT05602363RecruitingPhase 1
Docirbrutinib for CLL or lymphoma after prior treatments
This Phase 1 study tests docirbrutinib, a targeted pill treatment, in people with CLL/SLL or certain other B-cell lymphomas that have come back or didn’t respond to earlier therapy. The goal is to see whether it’s safe and whether it can control the disease after standard treatments have failed.
Orange, CaliforniaAges 18 years+ - NCT05603728Recruiting
Follow-up study for Exactech shoulder implants after surgery
This study follows people who get (or already had) a shoulder replacement to see how the implant is doing over time. It may help improve future care by tracking long-term performance and safety.
Laguna Woods, CaliforniaAges 21 years+ - NCT05607498RecruitingPhase 1
First study of EMB-07 for advanced cancers or lymphoma
This Phase 1 trial tests EMB-07, a new treatment, in people with advanced or hard-to-treat solid tumors or certain relapsed/refractory lymphomas. The goal is to find a safe dose and learn whether it can shrink tumors.
Frankston, VictoriaAges 18 years+ - NCT05607420RecruitingPhase 1/Phase 2
Testing a new cell therapy for relapsed lymphoma with CD20/CD22
This Phase 1/2 trial studies UCART20x22, a lab-made cell therapy, for people with certain types of relapsed or treatment-resistant B-cell non-Hodgkin lymphoma (NHL). It may help by targeting lymphoma cells that carry CD20 and/or CD22 markers and then testing safety and early effectiveness.
Chicago, IllinoisAges 18–80 - NCT05608681RecruitingPhase 1/Phase 2
Study drug for adults with eosinophilic esophagitis (EoE
This Phase 1/2 study tests EP-104GI in adults with eosinophilic esophagitis (EoE), a condition where certain immune cells cause inflammation in the food pipe. It may help improve symptoms and inflammation, and the study also includes a part where people who do well can switch to the active drug.
Sydney, New South WalesAges 18–75 - NCT05608668Recruiting
Breathing and activity coaching for kids with obesity and mild asthma
This trial tests an “inspiratory pulmonary rehabilitation” program—guided breathing and exercise training—for children who have obesity and mild asthma. It may help improve breathing control and exercise ability by teaching safe, structured breathing and activity habits.
Durham, North CarolinaAges 8–17 - NCT05615636RecruitingPhase 2
Study of four medicines for relapsed B-cell lymphoma
This Phase 2 trial tests a combination of several medicines for people whose lymphoma has come back or did not respond to prior treatment. It aims to shrink the lymphoma by using different ways to attack B-cell cancer.
Houston, TexasAges 18 years+ - NCT05616325Recruiting
Fertility follow-up for women after lymphoma chemotherapy
This study looks at long-term ovarian (egg-producing) fertility after chemotherapy for lymphoma, about 5 years after treatment ends. It may help doctors better understand pregnancy potential and guide future family-planning care.
LilleAges 18–45 - NCT05618041Recruiting
CAR-T treatment trial for relapsed or hard-to-treat blood cancers
This trial studies whether a CAR-T cell therapy is safe and effective for people with relapsed or refractory lymphoma, leukemia, or myeloma whose tumors have the right target markers. You may qualify if your health (heart, lungs, kidneys, liver) and blood counts are within required limits.
Taiyuan, ShanxiAges 14–75 - NCT05620680Recruiting
CD7 CAR-T for relapsed or resistant T-cell cancers
This trial studies a type of immune cell therapy (CAR-T) made from your own T-cells, designed to treat T-cell lymphoma or T-cell leukemia that has come back or didn’t respond. It may help by directing your immune system to attack the cancer, and it requires specific eligibility and safety checks.
Shenzhen, GuangdongAges 18–75 - NCT05620940RecruitingPhase 1
IV drug safety and absorption study in healthy men
This Phase 1 study tests two experimental medicines given by IV to healthy men. It checks safety and how the body absorbs and processes the drugs (their “pharmacokinetic” profile).
Herston, QueenslandAges 18–55 - NCT05623982RecruitingPhase 1/Phase 2
Study drug for lymphoma that has returned or did not respond
This Phase 1/2 study tests an injection called GNC-038 in people with non-Hodgkin’s lymphoma that has come back or is resistant to treatment. It aims to see how well the drug works and how safe it is for this group.
Beijing, Beijing MunicipalityAges 18–75 - NCT05626348RecruitingPhase 4
Test immune-modulator treatments for rheumatoid arthritis with knee trouble
This Phase 4 trial studies whether immune-modulator medicines improve symptoms and function in people with rheumatoid arthritis who have knee problems. It may also compare responses in osteoarthritis and healthy volunteers, depending on the group you fit.
Jinan, ShandongAges 18–80 - NCT05626400Recruiting
CAR T for relapsed T-ALL or T-LBL with CD7
This trial tests a type of immune therapy (CAR T cells) called Senl-T7 in people whose T-cell leukemia or lymphoma has come back or did not respond. It aims to target cancer cells that carry a marker called CD7.
Beijingcun, HebeiAges 2–70 - NCT05626712RecruitingPhase 1/Phase 2
CELZ-201 to preserve insulin production in early type 1 diabetes
This Phase 1/2 study tests whether CELZ-201 is safe and can help the body keep making some of its own insulin in people who were recently diagnosed with type 1 diabetes. You may be eligible if your diabetes started within the past year and your tests show you still have some insulin-making activity.
Miami, FloridaAges 18–35 - NCT05631886RecruitingPhase 1
Testing a cancer vaccine plus immune therapy for hard tumors
This early-phase trial tests whether combining a lab-made CAR-DC cancer vaccine with immune checkpoint medicines can shrink tumors that have specific genetic changes. It’s meant for people with advanced or returning (relapsed) solid tumors or certain lymphomas that match required tumor markers.
Beijing, Beijing MunicipalityAges 18–75 - NCT05632081Recruiting
Testing a new asthma control step-up approach
This trial studies how stepping up asthma treatment affects asthma control in people with mild to moderate asthma. You may be asked to use study inhalers correctly and track symptoms and lung tests to see if control improves.
DammamAges 12–80
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,230 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,742 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.